

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on Aug. 27, 1991



Dkt. No. 1280-4014US3  
Corres. and Mail  
**BOX AF**

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : David C. Ward, Pennina R. Langer & Alexander A. Waldrop III  
Serial No. : 07/130,097 Group : 183  
Filed : Dec. 7, 1987 Examiner: Crane  
For <sup>18m</sup> : MODIFIED NUCLEOTIDES AND METHODS OF PREPARING  
<sub>18s</sub> AND USING SAME  
8/28/91

Honorable Commissioner of Patents and Trademarks  
Washington, D.C. 20231

RECEIVED GROUP 180  
SEP 05 1991

Sir:

SUPPLEMENTAL AMENDMENT UNDER 37 CFR §1.116

This is a supplemental response to the Office Action dated March 25, 1991, to which a first response was filed on August 26, 1991. In that Amendment, Applicants inadvertantly neglected to respond to the rejection of Claims 138 and 139 under 25 USC §112, first and second paragraphs, because 2', 3'- and 3', 5'-cyclic monophosphates are allegedly not represented by a specific embodiment. The rejection is traversed and its withdrawal is requested in view of the following amendments and remarks.

IN THE CLAIMS

Please cancel Claim 139 without prejudice.

REMARKS

Entry of the foregoing amendment is requested. Applicants submit that the embodiment of remaining Claim 138 is supported in the specification as filed at page 40, lines 11-16. The 3', 5'-